• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Pharma & Human Health

Microbiotica Announces Positive Phase 1b Results for Precision Microbiome Co-Therapy in Advanced Melanoma

May 18, 2026 Microbiome Times

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial. […]

Finance

Kanvas Biosciences Secures $48M Series A to advance lead immuno-oncology drug

May 8, 2026 Microbiome Times

Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC. Additional participating investors include Gates Foundation, ATHOS […]

Pharma & Human Health

Engineered commensals for metabolic modulation of the gut-liver-brain axis

May 4, 2026 Microbiome Times

When the liver fails, toxins – such as ammonia – that should be filtered from the blood build up and reach the brain. The result is hepatic encephalopathy (HE), a devastating neurological complication of liver […]

Editor's Choice

LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis

May 1, 2026 Laurel Lagenaur

Bacterial vaginosis (BV) is one of the most common vaginal conditions affecting women of reproductive age worldwide, with prevalence rates estimated between 15% and 50%. It is a condition characterized by a disruption of the […]

Finance

EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS

April 30, 2026 Microbiome Times

EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome […]

Finance

mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome Therapeutics

April 28, 2026 Microbiome Times

mbiomics GmbH, a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases, today announced the successful third closing of its Series A round at €12 million, bringing the total round size to […]

Pharma & Human Health

Freya Biosciences announces positive Phase 1 data for IVF-related embryo implantation failure

April 16, 2026 Microbiome Times

Freya Biosciences, a clinical-stage immunology company developing therapies to treat inflammation and immune dysregulation in women, today announces positive topline results from its Phase 1 first-in-human clinical study evaluating FB301, a defined multi-strain Lactobacillus consortium […]

Editor's Choice

Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment

April 8, 2026 Professor Gilda Tachedjian BSc (Hons) PhD

Across women’s health, there is growing recognition of the urgent need for antibiotic‑sparing strategies that restore and sustain an optimal vaginal microbiota. Such an ecosystem is typically dominated by Lactobacillus crispatus, a species strongly associated […]

Finance

Women’s Health Innovation Is Not Failing – The System Around It Is

March 31, 2026 Maria Katsarou and Chrysi Sergaki

Women’s health is not constrained by a lack of scientific progress, but by systems that fail to recognise, prioritise, and translate it. Until those systems evolve, even the most promising innovations will struggle to reach […]

Editor's Choice

Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence

March 24, 2026 Microbiome Times

A global team of experts has identified a promising new approach to prevent recurrence of bacterial vaginosis (BV), a condition that affects millions of women worldwide. In a phase 1 randomized clinical trial of women […]

Pharma & Human Health

Qiagen unveils new high-throughput benchtop automation system

March 20, 2026 Microbiome Times

The new QIAsprint Connect is a next generation system for automated high-throughput nucleic acid purification, bringing together walk-away automation, flexible workflows and sustainable design – built for labs that want more control and less manual handling: High-throughput […]

Posts navigation

1 2 … 87 »

Sign Up to Free Newsletter

QIAGEN WEBINAR SERIES – REGISTER HERE

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
    May 1, 2026
  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
sign up

Sign up to the Microbiome Times newsletter